Merrill J Egorin
Overview
Explore the profile of Merrill J Egorin including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
147
Citations
3349
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
11.
Guo J, Clausen D, Beumer J, Parise R, Egorin M, Bravo-Altamirano K, et al.
Cancer Chemother Pharmacol
. 2012 Oct;
71(2):331-44.
PMID: 23108699
Purpose: Protein kinase D (PKD) mediates diverse biological responses including cell growth and survival. Therefore, PKD inhibitors may have therapeutic potential. We evaluated the in vitro cytotoxicity of two PKD...
12.
Parise R, Anyang B, Eiseman J, Egorin M, Covey J, Beumer J
Cancer Chemother Pharmacol
. 2012 Oct;
71(1):73-83.
PMID: 23053264
Benzaldehyde dimethane sulfonate (BEN, DMS612, NSC281612) is an alkylating agent with activity against renal cell carcinoma and is being evaluated clinically. To support clinical trials, we developed an LC-MS/MS assay...
13.
Pishvaian M, Slack R, Koh E, Beumer J, Hartley M, Cotarla I, et al.
Cancer Chemother Pharmacol
. 2012 Sep;
70(6):843-53.
PMID: 23014737
Purpose: Pre-clinical data suggest that combining imatinib with traditional cytotoxic chemotherapy may improve imatinib efficacy. We conducted a Phase I study of imatinib in combination with paclitaxel in patients with...
14.
Sherer E, Sale M, Pollock B, Belani C, Egorin M, Ivy P, et al.
J Pharmacokinet Pharmacodyn
. 2012 Jul;
39(4):393-414.
PMID: 22767341
A limitation in traditional stepwise population pharmacokinetic model building is the difficulty in handling interactions between model components. To address this issue, a method was previously introduced which couples NONMEM...
15.
Aregbe A, Sherer E, Egorin M, Scher H, Solit D, Ramanathan R, et al.
Cancer Chemother Pharmacol
. 2012 Mar;
70(1):201-5.
PMID: 22450873
Purpose: To identify sources of exposure variability for the tumor growth inhibitor 17-dimethylaminoethylamino-17-demethoxygeldanamycin (17-DMAG) using a population pharmacokinetic analysis. Methods: A total 67 solid tumor patients at 2 centers were...
16.
Bose P, Perkins E, Honeycut C, Wellons M, Stefan T, Jacobberger J, et al.
Cancer Chemother Pharmacol
. 2012 Feb;
69(6):1657-67.
PMID: 22349810
Purpose: Imatinib is an inhibitor of the Bcr-Abl tyrosine kinase; however, resistance is common. Flavopiridol, a cyclin-dependent kinase (CDK) inhibitor, down-regulates short-lived anti-apoptotic proteins via inhibition of transcription. In preclinical...
17.
Iyer G, Morris M, Rathkopf D, Slovin S, Steers M, Larson S, et al.
Cancer Chemother Pharmacol
. 2011 Nov;
69(4):1089-97.
PMID: 22124669
Purpose: To define maximum tolerated dose (MTD), clinical toxicities, and pharmacokinetics of 17-allylamino-17-demethoxygeldanamycin (17-AAG) when administered in combination with docetaxel once every 21 days in patients with advanced solid tumor...
18.
Mulder K, Egorin M, Sawyer M
Invest New Drugs
. 2011 Nov;
30(6):2400-2.
PMID: 22116657
Imatinib mesylate has proven activity in treating locally advanced or metastatic gastrointestinal stromal tumors (GIST). Drug interactions are particularly concerning as imatinib is extensively metabolized by the cytochrome P450 enzyme...
19.
Zamah A, Mauro M, Druker B, Oktay K, Egorin M, Cedars M, et al.
Oncologist
. 2011 Sep;
16(10):1422-7.
PMID: 21948652
Imatinib mesylate is the first in a family of highly effective, minimally toxic, targeted agents used widely to treat Philadelphia-positive leukemias and selected other cancers, leading to a steady rise...
20.
Stathis A, Hotte S, Chen E, Hirte H, Oza A, Moretto P, et al.
Clin Cancer Res
. 2011 Sep;
27(15S).
PMID: 21152384
PURPOSE: This phase I study evaluated the safety, tolerability, pharmacokinetics and preliminary efficacy of the combination of decitabine with vorinostat. PATIENTS AND METHODS: Patients with advanced solid tumors or non-Hodgkin's...